Literature DB >> 18669630

A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection.

Nicola J MacLaine1, Bodil Oster, Bettina Bundgaard, Jennifer A Fraser, Carolyn Buckner, Pedro A Lazo, David W Meek, Per Höllsberg, Ted R Hupp.   

Abstract

The tumor suppressor protein p53 is activated by distinct cellular stresses including radiation, hypoxia, type I interferon, and DNA/RNA virus infection. The transactivation domain of p53 contains a phosphorylation site at Ser20 whose modification stabilizes the binding of the transcriptional co-activator p300 and whose mutation in murine transgenics induces B-cell lymphoma. Although the checkpoint kinase CHK2 is implicated in promoting Ser20 site phosphorylation after irradiation, the enzyme that triggers this phosphorylation after DNA viral infection is undefined. Using human herpesvirus 6B (HHV-6B) as a virus that induces Ser20 site phosphorylation of p53 in T-cells, we sought to identify the kinase responsible for this virus-induced p53 modification. The p53 Ser20 kinase was fractionated and purified using cation, anion, and dye-ligand exchange chromatography. Mass spectrometry identified casein kinase 1 (CK1) and vaccinia-related kinase 1 (VRK1) as enzymes that coeluted with virus-induced Ser20 site kinase activity. Immunodepletion of CK1 but not VRK1 removed the kinase activity from the peak fraction, and bacterially expressed CK1 exhibited Ser20 site kinase activity equivalent to that of the virus-induced native CK1. CK1 modified p53 in a docking-dependent manner, which is similar to other known Ser20 site p53 kinases. Low levels of the CK1 inhibitor D4476 selectively inhibited HHV-6B-induced Ser20 site phosphorylation of p53. However, x-ray-induced Ser20 site phosphorylation of p53 was not blocked by D4476. These data highlight a central role for CK1 as the Ser20 site kinase for p53 in DNA virus-infected cells but also suggest that distinct stresses may selectively trigger different protein kinases to modify the transactivation domain of p53 at Ser20.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669630      PMCID: PMC2661408          DOI: 10.1074/jbc.M804433200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15.

Authors:  N Dumaz; D M Milne; D W Meek
Journal:  FEBS Lett       Date:  1999-12-17       Impact factor: 4.124

2.  Signaling to p53: the use of phospho-specific antibodies to probe for in vivo kinase activation.

Authors:  Ashley L Craig; Susan E Bray; Lee E Finlan; Neil M Kernohan; Ted R Hupp
Journal:  Methods Mol Biol       Date:  2003

3.  DNA-dependent acetylation of p53 by the transcription coactivator p300.

Authors:  David Dornan; Harumi Shimizu; Neil D Perkins; Ted R Hupp
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

4.  The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Authors:  David Dornan; Harumi Shimizu; Lindsay Burch; Amanda J Smith; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

5.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Authors:  S Y Shieh; J Ahn; K Tamai; Y Taya; C Prives
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

6.  Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner.

Authors:  Chris Boutell; Roger D Everett
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain.

Authors:  Ashley Craig; Mary Scott; Lindsay Burch; Graeme Smith; Kathryn Ball; Ted Hupp
Journal:  EMBO Rep       Date:  2003-08       Impact factor: 8.807

8.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

9.  D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a.

Authors:  Graham Rena; Jenny Bain; Matthew Elliott; Philip Cohen
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

10.  Questioning the role of checkpoint kinase 2 in the p53 DNA damage response.

Authors:  Jinwoo Ahn; Marshall Urist; Carol Prives
Journal:  J Biol Chem       Date:  2003-03-24       Impact factor: 5.157

View more
  23 in total

1.  Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone deacetylation.

Authors:  Samik Chakraborty; Kaushik Das; Shilpi Saha; Minakshi Mazumdar; Argha Manna; Sreeparna Chakraborty; Shravanti Mukherjee; Poulami Khan; Arghya Adhikary; Suchismita Mohanty; Samit Chattopadhyay; Subhash C Biswas; Gaurisankar Sa; Tanya Das
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

2.  Isoform specific phosphorylation of p53 by protein kinase CK1.

Authors:  Andrea Venerando; Oriano Marin; Giorgio Cozza; Victor H Bustos; Stefania Sarno; Lorenzo Alberto Pinna
Journal:  Cell Mol Life Sci       Date:  2009-12-30       Impact factor: 9.261

3.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.

Authors:  Erin G Worrall; Bartosz Wawrzynow; Liam Worrall; Malcolm Walkinshaw; Kathryn L Ball; Ted R Hupp
Journal:  J Chem Biol       Date:  2009-05-16

4.  CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.

Authors:  Anne-Sophie Huart; Nicola J MacLaine; David W Meek; Ted R Hupp
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

5.  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.

Authors:  Andrii Monastyrskyi; Napon Nilchan; Victor Quereda; Yoshihiko Noguchi; Claudia Ruiz; Wayne Grant; Michael Cameron; Derek Duckett; William Roush
Journal:  Bioorg Med Chem       Date:  2017-12-15       Impact factor: 3.641

6.  Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo.

Authors:  Hiroyuki Niida; Kazuhiro Murata; Midori Shimada; Kumiko Ogawa; Kumiko Ohta; Kyoko Suzuki; Hidetsugu Fujigaki; Aik Kia Khaw; Birendranath Banerjee; M Prakash Hande; Tomomi Miyamoto; Ichiro Miyoshi; Tomoyuki Shirai; Noboru Motoyama; Mireille Delhase; Ettore Appella; Makoto Nakanishi
Journal:  EMBO J       Date:  2010-09-10       Impact factor: 11.598

Review 7.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

8.  The flaviviral methyltransferase is a substrate of Casein Kinase 1.

Authors:  Dipankar Bhattacharya; Israrul H Ansari; Rob Striker
Journal:  Virus Res       Date:  2009-01-29       Impact factor: 3.303

9.  The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway.

Authors:  Nicola J Maclaine; Ted R Hupp
Journal:  Aging (Albany NY)       Date:  2009-05-07       Impact factor: 5.682

10.  Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Authors:  Najma Rachidi; Jean François Taly; Emilie Durieu; Olivier Leclercq; Nathalie Aulner; Eric Prina; Pascale Pescher; Cedric Notredame; Laurent Meijer; Gerald F Späth
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.